
Outset Medical (OM) Stock Forecast & Price Target
Outset Medical (OM) Analyst Ratings
Bulls say
Outset Medical Inc. has demonstrated strong performance in console sales, exceeding expectations in Q3 despite a delay in one large order, positioning the company for profitability amid ongoing cost reduction and manufacturing efficiency initiatives. The continued improvement in gross margins, which are projected to reach the high-30s for FY25, supports the company's long-term goal of achieving 50% gross margin, further enhancing financial stability. Additionally, the company is on track to meet its cash burn target of under $50 million for 2025, coupled with accelerated consumables ordering and a growing Tablo pipeline, which strengthens the outlook for future revenue growth.
Bears say
Outset Medical Inc. is experiencing significant challenges as evidenced by a disappointing quarter where total revenues fell short of consensus estimates, primarily due to weak Consumables revenue driven by reduced orders from acute care customers. The company's revised full-year revenue guidance reflects a decline to $115M-$120M from an earlier $122M-$126M, indicating ongoing difficulties in generating consistent sales. Furthermore, anticipated delays in enterprise deal timing and potential salesforce disruption following the departure of its head of sales contribute to a negative outlook for the company's financial performance moving forward.
This aggregate rating is based on analysts' research of Outset Medical and is not a guaranteed prediction by Public.com or investment advice.
Outset Medical (OM) Analyst Forecast & Price Prediction
Start investing in Outset Medical (OM)
Order type
Buy in
Order amount
Est. shares
0 shares